Cargando…

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

Carboplatin is the cornerstone of ovarian cancer (OC) treatment, while platinum-response, dependent on interindividual variability, is the major prognostic factor for long-term outcomes. This retrospective study was focused on explorative search of genetic polymorphisms in the Absorption, Distributi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staropoli, Nicoletta, Arbitrio, Mariamena, Salvino, Angela, Scionti, Francesca, Ciliberto, Domenico, Ingargiola, Rossana, Labanca, Caterina, Agapito, Giuseppe, Iuliano, Eleonora, Barbieri, Vito, Cucè, Maria, Zuccalà, Valeria, Cannataro, Mario, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138265/ https://www.ncbi.nlm.nih.gov/pubmed/35625946 http://dx.doi.org/10.3390/biomedicines10051210

Ejemplares similares

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
por: Arbitrio, Mariamena, et al.
Publicado: (2018)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine
por: Agapito, Giuseppe, et al.
Publicado: (2020)

DMET-Analyzer: automatic analysis of Affymetrix DMET Data
por: Guzzi, Pietro Hiram, et al.
Publicado: (2012)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
por: Staropoli, Nicoletta, et al.
Publicado: (2013)

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2021)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
por: Tassone, Pierfrancesco, et al.
Publicado: (2023)

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation
por: Staropoli, Nicoletta, et al.
Publicado: (2016)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
por: Di Martino, Maria T, et al.
Publicado: (2011)

miR-22 suppresses DNA ligase III addiction in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2018)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin
por: Caracciolo, Daniele, et al.
Publicado: (2022)

Analysis of miRNA, mRNA, and TF interactions through network-based methods
por: Guzzi, Pietro H, et al.
Publicado: (2015)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

An Exploratory Application of Multilayer Networks and Pathway Analysis in Pharmacogenomics
por: Milano, Marianna, et al.
Publicado: (2023)

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
por: Grillone, Katia, et al.
Publicado: (2022)

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
por: Ciliberto, Domenico, et al.
Publicado: (2023)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas
por: Polerà, Nicoletta, et al.
Publicado: (2023)

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma
por: Scionti, Francesca, et al.
Publicado: (2023)

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
por: Di Martino, Maria Teresa, et al.
Publicado: (2022)

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2016)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
por: Grillone, Katia, et al.
Publicado: (2020)

Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
por: d’Apolito, Maria, et al.
Publicado: (2022)

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival
por: Botta, C, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1eds2m13j92s1famj1pk797vkl